-transparent.png){kind=logo}
1. A gas-chromatographic assay for the anticonvulsant drug ethotoin in plasma has been used to establish a kinetic basis for therapy in eight newly diagnosed epileptic patients. 2. Only a small fraction of ethotoin was excreted unchanged. Elimination curves were only rectilinear below a plasma concentration of 8 mg/l. During constant medication plasma concentrations tended to decrease in the first week. Steady-state plasma levels varied considerably between individuals. For all patients the plasma concentration/dose ratio increased with increasing dose. 3. Most of the results point to dose-dependent elimination kinetics in the therapeutic range and parallel what is known for phenytoin. Control of therapy by measurement of plasma levels of ethotoin is accordingly advocated.
Sjö, and
E F Hvidberg, and
N E Larsen, and
J Naestoft
March 1983,
Clinical pharmacology and therapeutics,
Sjö, and
E F Hvidberg, and
N E Larsen, and
J Naestoft
January 1993,
IARC scientific publications,
Sjö, and
E F Hvidberg, and
N E Larsen, and
J Naestoft
February 1990,
Toxicology letters,
Sjö, and
E F Hvidberg, and
N E Larsen, and
J Naestoft
January 1983,
Cancer treatment reports,
Sjö, and
E F Hvidberg, and
N E Larsen, and
J Naestoft
August 1989,
British journal of clinical pharmacology,
Sjö, and
E F Hvidberg, and
N E Larsen, and
J Naestoft
May 1979,
Clinical pharmacology and therapeutics,
Sjö, and
E F Hvidberg, and
N E Larsen, and
J Naestoft
October 1986,
The Journal of allergy and clinical immunology,
Sjö, and
E F Hvidberg, and
N E Larsen, and
J Naestoft
August 1989,
The Journal of clinical psychiatry,
Sjö, and
E F Hvidberg, and
N E Larsen, and
J Naestoft
March 1958,
Journal of the American Medical Association,
Sjö, and
E F Hvidberg, and
N E Larsen, and
J Naestoft
January 1979,
Clinical pharmacokinetics,
